Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Mixed treatment comparison of the treatment discontinuations of biologic disease-modifying antirheumatic drugs in adults with rheumatoid arthritis.

Desai RJ, Hansen RA, Rao JK, Wilkins TM, Harden EA, Yuen A, Jonas DE, Roubey R, Jonas B, Gartlehner G, Lux L, Donahue KE.

Ann Pharmacother. 2012 Nov;46(11):1491-505. doi: 10.1345/aph.1R203. Epub 2012 Oct 23. Review.

PMID:
23092868
2.

Summary of AHRQ's comparative effectiveness review of drug therapy for rheumatoid arthritis (RA) in adults--an update.

Singh JA, Cameron DR.

J Manag Care Pharm. 2012 May;18(4 Supp C):S1-18. Review.

PMID:
22656072
3.

Biologics for rheumatoid arthritis: an overview of Cochrane reviews.

Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Tanjong Ghogomu E, Tugwell P.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007848. doi: 10.1002/14651858.CD007848.pub2. Review.

PMID:
19821440
4.

Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.

Singh JA, Hossain A, Tanjong Ghogomu E, Mudano AS, Maxwell LJ, Buchbinder R, Lopez-Olivo MA, Suarez-Almazor ME, Tugwell P, Wells GA.

Cochrane Database Syst Rev. 2017 Mar 10;3:CD012591. doi: 10.1002/14651858.CD012591. Review.

PMID:
28282491
5.

Drug Therapy for Rheumatoid Arthritis in Adults: An Update [Internet].

Donahue KE, Jonas DE, Hansen RA, Roubey R, Jonas B, Lux LJ, Gartlehner G, Harden E, Wilkins T, Peravali V, Bangdiwala SI, Yuen A, Thieda P, Morgan LC, Crotty K, Desai R, Van Noord M.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Apr.

6.

Adverse effects of biologics: a network meta-analysis and Cochrane overview.

Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, Filippini G, Skoetz N, Francis D, Lopes LC, Guyatt GH, Schmitt J, La Mantia L, Weberschock T, Roos JF, Siebert H, Hershan S, Lunn MP, Tugwell P, Buchbinder R.

Cochrane Database Syst Rev. 2011 Feb 16;(2):CD008794. doi: 10.1002/14651858.CD008794.pub2. Review.

PMID:
21328309
7.

Anakinra for rheumatoid arthritis.

Mertens M, Singh JA.

Cochrane Database Syst Rev. 2009 Jan 21;(1):CD005121. doi: 10.1002/14651858.CD005121.pub3. Review.

PMID:
19160248
8.

A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis.

Turkstra E, Ng SK, Scuffham PA.

Curr Med Res Opin. 2011 Oct;27(10):1885-97. doi: 10.1185/03007995.2011.608655. Epub 2011 Aug 18. Review.

PMID:
21848493
9.

Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis.

Hazlewood GS, Barnabe C, Tomlinson G, Marshall D, Devoe DJ, Bombardier C.

Cochrane Database Syst Rev. 2016 Aug 29;(8):CD010227. doi: 10.1002/14651858.CD010227.pub2. Review.

PMID:
27571502
10.

Impact of biologic therapy on functional status in patients with rheumatoid arthritis--a meta-analysis.

Callhoff J, Weiß A, Zink A, Listing J.

Rheumatology (Oxford). 2013 Dec;52(12):2127-35. doi: 10.1093/rheumatology/ket266. Epub 2013 Aug 14. Review.

PMID:
23946435
11.
12.

Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.

Liu Y, Wu EQ, Bensimon AG, Fan CP, Bao Y, Ganguli A, Yang M, Cifaldi M, Mulani P.

Adv Ther. 2012 Jul;29(7):620-34. doi: 10.1007/s12325-012-0035-7. Epub 2012 Jul 27.

PMID:
22843208
13.

A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal.

Choy EH, Smith C, Doré CJ, Scott DL.

Rheumatology (Oxford). 2005 Nov;44(11):1414-21. Epub 2005 Jul 19. Review.

PMID:
16030080
14.

A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis.

Mandema JW, Salinger DH, Baumgartner SW, Gibbs MA.

Clin Pharmacol Ther. 2011 Dec;90(6):828-35. doi: 10.1038/clpt.2011.256. Epub 2011 Nov 2.

PMID:
22048227
15.

The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis.

Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN.

J Rheumatol. 2006 Dec;33(12):2398-408. Review.

PMID:
17225293
17.

Mixed treatment comparison of efficacy and tolerability of biologic agents in patients with rheumatoid arthritis.

Hochberg MC, Berry S, Broglio K, Rosenblatt L, Nadkarni A, Trivedi D, Hebden T.

Curr Med Res Opin. 2013 Oct;29(10):1213-22. doi: 10.1185/03007995.2013.813839. Epub 2013 Jul 25. Review.

PMID:
23745516
18.

Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.

Weaver AL, Lautzenheiser RL, Schiff MH, Gibofsky A, Perruquet JL, Luetkemeyer J, Paulus HE, Xia HA, Leff JA; RADIUS Investigators.

Curr Med Res Opin. 2006 Jan;22(1):185-98.

PMID:
16393444
19.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

20.

Have traditional DMARDs had their day? Effectiveness of parenteral gold compared to biologic agents.

Rau R.

Clin Rheumatol. 2005 Jun;24(3):189-202. Epub 2004 Jul 24. Review.

PMID:
15940552

Supplemental Content

Support Center